These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 24354659)
1. Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials. Rao NP; Remington G Expert Opin Pharmacother; 2014 Feb; 15(3):373-83. PubMed ID: 24354659 [TBL] [Abstract][Full Text] [Related]
2. Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials. Rao NP; Remington G Expert Opin Investig Drugs; 2013 Jul; 22(7):881-94. PubMed ID: 23639138 [TBL] [Abstract][Full Text] [Related]
3. Investigational dopamine antagonists for the treatment of schizophrenia. Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU Expert Opin Investig Drugs; 2017 Jun; 26(6):687-698. PubMed ID: 28443355 [TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. Lockwood JT; Remington G Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007 [TBL] [Abstract][Full Text] [Related]
5. Drugs in development for the treatment of schizophrenia. Emsley R Expert Opin Investig Drugs; 2009 Aug; 18(8):1103-18. PubMed ID: 19589093 [TBL] [Abstract][Full Text] [Related]
6. Potential serotonergic agents for the treatment of schizophrenia. Garay RP; Bourin M; de Paillette E; Samalin L; Hameg A; Llorca PM Expert Opin Investig Drugs; 2016; 25(2):159-70. PubMed ID: 26576669 [TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for schizophrenia: an update. Köster LS; Carbon M; Correll CU Expert Opin Emerg Drugs; 2014 Dec; 19(4):511-31. PubMed ID: 25234340 [TBL] [Abstract][Full Text] [Related]
8. Recent developments in the discovery of novel antipsychotic agents modualating dopamine and serotonin receptors. Li X; Ma S Curr Drug Targets; 2013 Jul; 14(8):899-918. PubMed ID: 23701299 [TBL] [Abstract][Full Text] [Related]
9. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Remington G; Agid O; Foussias G Expert Rev Neurother; 2011 Apr; 11(4):589-607. PubMed ID: 21469931 [TBL] [Abstract][Full Text] [Related]
11. Central dopaminergic mechanisms in schizophrenia. Owen F; Crow TJ; Poulter M Acta Psychiatr Belg; 1987; 87(5):552-65. PubMed ID: 2897760 [TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics: mechanism of action. Seeman P Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706 [TBL] [Abstract][Full Text] [Related]
13. Improving Current Treatments for Schizophrenia. Maric NP; Jovicic MJ; Mihaljevic M; Miljevic C Drug Dev Res; 2016 Nov; 77(7):357-367. PubMed ID: 27633376 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Garay RP; Citrome L; Samalin L; Liu CC; Thomsen MS; Correll CU; Hameg A; Llorca PM Expert Opin Pharmacother; 2016; 17(7):921-36. PubMed ID: 26831200 [TBL] [Abstract][Full Text] [Related]
15. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Kuroki T; Nagao N; Nakahara T Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update. Scharfetter J Pharmacogenomics; 2004 Sep; 5(6):691-8. PubMed ID: 15335289 [TBL] [Abstract][Full Text] [Related]
17. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Meltzer HY; Huang M Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033 [TBL] [Abstract][Full Text] [Related]
18. Brexpiprazole for the treatment of schizophrenia. Hsu WY; Lane HY; Lin CH Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809 [TBL] [Abstract][Full Text] [Related]
19. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Miyamoto S; Jarskog LF; Fleischhacker WW Curr Opin Psychiatry; 2013 Mar; 26(2):158-65. PubMed ID: 23286991 [TBL] [Abstract][Full Text] [Related]
20. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]